ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nintedanib

Also written as “Nintedanib”, “BIBF 1120” and “Nintedanib (BIBF1120)”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Carcinoma, Non-Small-Cell Lung · Pulmonary Fibrosis · Lung Diseases, Interstitial · Neoplasms, led by 3 companies.

Drug pageNintedanib: every studyAll 141 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 16, 201564 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only620 open or runningphase 4since Oct 16, 2015Aug 9, 2007none ahead
Mannkindits history only10 open or runningphase 1since Jan 7, 2026Jan 7, 2026none ahead
PureTech10 open or runningphase 1since Nov 20, 2024Nov 20, 2024none ahead

Also a collaborator on its studies: Novotech (Australia) Pty and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of PureTech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2024First study: phase 1 study in Pulmonary FibrosisFirst studyNCT06717100 · 24 enrolled · Australia

TargetBeta

“Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

The one study PureTech leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06717100Pulmonary Fibrosis · Australia1CompletedFeb 17, 202524

How it is read

Names in the registry

  • “Nintedanib”, 43 entries
  • “BIBF 1120”, 26 entries
  • “nintedanib”, 4 entries
  • “Nintedanib (BIBF1120)”, 2 entries
  • “Nintedanib high dose”, 2 entries

Codes read as this program: MNKD201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.